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Abstract Purpose: Sepsis is a
major health burden worldwide. Pre-
clinical investigations in animals and
retrospective studies in patients have
suggested that inhibition of platelets
may improve the outcome of sepsis. In
this study we investigated whether
chronic antiplatelet therapy impacts on
the presentation and outcome of sepsis,
and the host response.Methods: We
performed a prospective observational
study in 972 patients admitted with
sepsis to the mixed intensive care units
(ICUs) of two hospitals in the Nether-
lands between January 2011 and July
2013. Of them, 267 patients (27.5 %)
were on antiplatelet therapy (95.9 %
acetylsalicylic acid) before admission.
To account for differential likelihoods of
receiving antiplatelet therapy, a
propensity score was constructed,
including variables associated with use
of antiplatelet therapy. Cox proportional
hazards regression was used to estimate
the association of antiplatelet therapy
with mortality. Results: Antiplatelet
therapy was not associated with sepsis
severity at presentation, the primary
source of infection, causative patho-
gens, the development of organ failure
or shock during ICU stay, or mortality
up to 90 days after admission, in either
unmatched or propensity-matched
analyses. Antiplatelet therapy did not
modify the values of 19 biomarkers
providing insight into hallmark host
responses to sepsis, including activa-
tion of the coagulation system, the
vascular endothelium, the cytokine
network, and renal function, during the
first 4 days after ICU admission.
Conclusions: Pre-existing antiplate-
let therapy is not associated with
alterations in the presentation or out-
come of sepsis, or the host response.
Keywords Sepsis  Antiplatelet 
Mortality  Intensive care unit
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Introduction
Sepsis is a life-threatening condition caused by an injurious
host response to infection with an estimated incidence of
over 19 million cases per year worldwide [1, 2]. Sepsis
plays a prominent role in patients admitted to intensive
care units (ICUs) where it is highly associated with mor-
bidity and mortality [3]. During sepsis, triggering of
inflammatory and coagulation cascades, together with
endothelial damage, invariably leads to activation of pla-
telets [4, 5]. Platelet activation can be further stimulated by
direct interactions with pathogens [4, 6]. Platelets are
essential components of primary hemostasis and in addi-
tion can aid the host in eliminating invading pathogens by
facilitating a variety of bactericidal effector mechanisms
[4, 6, 7]. However, during uncontrolled infection platelet
activation contributes to sepsis complications [4, 8].
Indeed, several preclinical studies have shown beneficial
effects of antiplatelet therapy in sepsis models [4].
Antiplatelet drugs such as clopidogrel or acetylsali-
cyclic acid are widely used in the secondary prevention of
cardiovascular, cerebrovascular, and peripheral arterial
thrombosis. To date, there has been no randomized con-
trolled clinical trial investigating the effect of antiplatelet
therapy in sepsis. Retrospective studies showed a bene-
ficial effect of pre-existing therapy with an antiplatelet
drug with respect to organ failure, duration of ICU and
hospital stay, and mortality in critically ill patients [4, 8,
9]. However, most studies in critically ill patients with
infection were small and/or included patient groups that
were not matched for potential confounding factors, such
as comorbidity and other chronic medication. In addition,
the effect of antiplatelet therapy on the host response to
critical illness has not been studied in patients.
The aim of the present prospective observational study
was to determine the association between pre-existing
antiplatelet therapy and presentation and outcome of sep-
sis, and induction of biomarkers providing insight into
hallmark host responses, making use of a large well-de-
fined cohort of patients admitted to the ICU. We
hypothesized that chronic antiplatelet therapy may improve
sepsis outcome by mitigating the derailed host response.
Methods
Study design, patients, and definitions
This study was conducted as part of the Molecular Diag-
nosis and Risk Stratification of Sepsis (MARS) project, a
prospective observational study in the mixed ICUs of two
tertiary teaching hospitals (Academic Medical Center in
Amsterdam and University Medical Center Utrecht) in the
Netherlands between January 2011 and January 2014
(ClinicalTrials.gov identifier NCT01905033) [10, 11].
Both ICUs comply with the Surviving Sepsis Guidelines
[12]. Dedicated observers prospectively collected the fol-
lowing data from all patients: demographics, comorbidities
(including the Charlson comorbidity index [13]), chronic
medication use, ICU admission characteristics (including
the Acute Physiology and Chronic Health Evaluation
(APACHE) IV score and the acute physiology score [14]),
and daily physiological measurements, severity scores
(including Sequential Organ Failure Assessment (SOFA)
scores [15]), and culture results. Organ failure was defined
as a SOFA score of 3 or greater, except for cardiovascular
failure for which a score of 1 or more was used [16]. Shock
was defined as the use of vasopressors (noradrenaline) for
hypotension in a dose of 0.1 lg/kg/min during at least
50 % of the ICU day. The plausibility of infection was post
hoc scored on the basis of all available evidence and
classified on a 4-point scale (none, possible, probable, or
definite) according to Centers for Disease Control and
Prevention [17] and International Sepsis Forum consensus
definitions [18], as described in detail previously [10].
Daily (at admission and at 6 A.M. thereafter) left-over
plasma (obtained from blood drawn for patient care) was
stored within 4 h at -80 C. The medical ethical com-
mittees of both study centers gave approval for an opt-out
consent method (IRB no. 10-056C). The Municipal Per-
sonal Records Database was consulted to determine
survival up to 1 year after ICU admission.
For the current analysis we selected all patients
included in the MARS study between January 2011 and
July 2013 with sepsis, diagnosed within 24 h after
admission, defined as a definite or probable infection [10]
combined with at least one of general, inflammatory,
hemodynamic, organ dysfunction, or tissue perfusion
parameters derived from the 2001 International Sepsis
Definitions Conference [19]. Readmissions, admissions
for elective surgery, and patients transferred from another
ICU were excluded, except for patients referred to one of
the study centers on the day of admission.
Biomarker measurements
All measurements were done in EDTA anticoagulated
plasma obtained within 24 h after admission (day 0) and
days 2 and 4. Assays are described in the online supple-
ment. Normal biomarker values were acquired from
EDTA plasma from 27 age- and gender-matched healthy
volunteers, from whom written informed consent was
obtained.
Statistical analysis
Data analyses were performed in R (v3.1.1). Baseline
characteristics of study groups were compared with the
Chi-square test for categorical variables and t test or
Wilcoxon rank sum test for continuous variables. Mixed-
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effects models were executed to analyze repeated mea-
surements. Propensity score matching and Cox
proportional hazards regression analyses were performed
as described in the online supplement. To account for
random effects of propensity matching, appropriate tests
were used in the propensity-matched cohort: paired t test,
Wilcoxon signed-rank test, McNemar test, stratified log-
rank test, and Cox frailty model. Because of missing
plasma samples in both groups (discharge, death, logis-
tics), a paired test was not suitable to compare plasma
sample measurements in the matched cohort. P values
below 0.05 were considered significant.
Results
Patients
A total of 6994 admissions were included in the MARS
study from January 2011 until July 2013, of which 1483
involved an admission diagnosis of sepsis. A total of 129
transfers from other ICUs and 250 readmissions were
excluded; prior use of medication could not be retrieved
in 44 cases. In addition, 88 patients admitted for elective
surgery were excluded. As a result, 972 patients were
included for analysis (523 in AMC, 449 in UMCU), of
whom 267 (27.5 %) were on chronic antiplatelet therapy
prior to ICU admission. Baseline characteristics are
shown in Table 1. Acetylsalicylic acid was the most
commonly used antiplatelet drug (95.9 %), whereas
clopidogrel and dipyridamole were used by 16.1 and
12.4 % of the patients on antiplatelet therapy, respec-
tively; 67 patients (25.1 %) were on more than one
antiplatelet drug. Patients with antiplatelet therapy were
older than those without, and more frequently men. As
expected, cardiovascular disease was much more preva-
lent in antiplatelet therapy users, together with diabetes
mellitus and COPD; non-users had a greater frequency of
malignancies. In accordance, antiplatelet therapy users
were also more frequently on other vasoactive drugs,
including statins, ACE inhibitors, beta-blockers, and cal-
cium channel blockers. Sites of infection and causative
pathogens did not differ between users and non-users of
antiplatelet agents (Supplemental Table 1).
Considering the large baseline differences between
users and non-users of antiplatelet drugs at baseline, we
constructed a propensity-matched cohort. Thus 961
patients were assigned a propensity score for receiving
antiplatelet therapy (99 % of all patients included); 11
patients were not given a score as a result of missing data.
As a result of the unequal distribution of propensity scores
between the groups (Supplemental Fig. 1), 150 of 267
antiplatelet users could be matched to non-users. The
propensity-matched patients were similar with regard to
comorbidity, chronic medication, and demographic dis-
tribution (Table 1).
Administration of antiplatelet therapy during ICU
admission was dependent on the judgment of the medical
team; at least one dose in the first 2 days of admission
was received by 43.8 % of antiplatelet users in the
unmatched cohort and by 40.0 % in the matched cohort.
Sepsis severity on admission
APACHE IV and SOFA scores and the presence of organ
failure and shock were similar between chronic users and
non-users of antiplatelet therapy, both in the unmatched
and the propensity-matched cohort analyses (Table 1).
Likewise, the use of supportive therapy (mechanical
ventilation and renal replacement therapy) during the first
24 h after admission were similar between groups.
Together these data suggest that the use of antiplatelet
therapy does not influence the severity of sepsis upon
admission to the ICU.
Sepsis outcomes
Table 2 and Fig. 1 show unadjusted outcomes of the
unmatched and propensity-matched patients stratified
according to the use of antiplatelet therapy. Irrespective of
matching, antiplatelet therapy did not impact on the
occurrence of organ failure or shock during ICU admis-
sion, or on mortality in the ICU, or at 30, 60, or 90 days.
In a Cox proportional hazards model, APS was signifi-
cantly associated with mortality rate at 30, 60, and
90 days in both the unmatched and matched cohort,
whereas antiplatelet therapy was not. To confirm our
findings, propensity scores were included in the regres-
sion model of the complete cohort, as a different method
to adjust for propensity bias. Again, antiplatelet therapy
was not associated with mortality, either at 30 days
(Table 3), 60 days (Supplemental Table 2), or 90 days
(Supplemental Table 3).
Subgroup and sensitivity analyses
In addition, we compared patients with only acetylsali-
cylic acid therapy to antiplatelet non-users, and patients
receiving more than one antiplatelet drug with antiplatelet
non-users. Outcomes from these patient groups were
comparable to the initial cohort (data not shown). To
evaluate the association between antiplatelet therapy and
mortality in patients with septic shock we performed a
subgroup analysis in this subset of patients (Supplemental
Table 4). In addition, we included the interaction with
antiplatelet therapy in the Cox proportional hazards
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models of the complete cohorts (Supplemental Table 5).
These analyses did not change our findings: antiplatelet
therapy was not associated with altered outcome. We
defined septic shock as the use of vasopressors
(noradrenaline) for hypotension for more than 50 % of the
ICU day [20, 21]. We performed additional analyses in
which shock was defined as the use vasopressors for
hypotension for more than 6 h. Using this shock
Table 1 Baseline characteristics of unmatched and propensity-matched patients















Age, years, mean [SD] 67.6 [10.4] 58.8 [15.4] \0.0001 66.1 [10.5] 65.7 [10.7] 0.66
Gender, male (%) 184 (68.9) 402 (57) \0.001 91 (60.7) 96 (64) 0.61
Race, white (%) 242 (90.6) 617 (87.5) 0.15 140 (93.3) 137 (91.3) 0.65
BMI, kg/m2, mean [SD] 26.2 [6.2] 25.8 [6.1] 0.40 26.3 [6.7] 26.2 [5.9] 0.97
Admission type, medical (%) 220 (82.4) 564 (80) 0.41 124 (82.7) 128 (85.3) 0.64
Comorbidities
Charlson score, median [IQR]a 2 [1–3] 1 [0–2] \0.001 2 [1–3] 2 [1–2] 0.31
Cerebrovascular disease (%) 54 (20.2) 37 (5.2) \0.001 27 (18) 21 (14) 0.38
Chronic cardiovascular insufficiency (%) 18 (6.7) 20 (2.8) 0.0065 8 (5.3) 9 (6) 1
Chronic renal insufficiency (%) 63 (23.6) 83 (11.8) \0.001 33 (22) 31 (20.7) 0.88
Congestive heart failure (%) 25 (9.4) 21 (3) \0.001 11 (7.3) 11 (7.3) 1
COPD (%) 62 (23.2) 88 (12.5) \0.001 30 (20) 37 (24.7) 0.39
Diabetes mellitus (%) 96 (36) 109 (15.5) \0.001 45 (30) 46 (30.7) 1
Hematologic malignancy (%) 13 (4.9) 65 (9.2) 0.037 10 (6.7) 8 (5.3) 0.81
Hypertension (%) 127 (47.6) 175 (24.8) \0.001 60 (40) 55 (36.7) 0.63
Immune deficiency (%) 47 (17.6) 167 (23.7) 0.05 34 (22.7) 30 (20) 0.65
Liver cirrhosis (%) 6 (2.2) 16 (2.3) 1 4 (2.7) 3 (2) 1
Metastatic malignancy (%) 4 (1.5) 35 (5) 0.012 3 (2) 0 (0) 0.25
Myocardial infarction (history of) (%) 72 (27) 20 (2.8) \0.001 15 (10) 17 (11.3) 0.81
Non-metastatic malignancy (%) 44 (16.5) 88 (12.5) 0.11 24 (16) 20 (13.3) 0.63
Peripheral vascular disease (%) 68 (25.5) 45 (6.4) \0.001 22 (14.7) 20 (13.3) 0.87
Chronic medication
ACE inhibitors and ARBs (%) 131 (49.1) 157 (22.3) \0.001 66 (44) 66 (44) 1
Anticoagulants (%) 33 (12.4) 123 (17.4) 0.06 22 (14.7) 26 (17.3) 0.63
Beta-blockers (%) 152 (56.9) 166 (23.5) \0.001 71 (47.3) 65 (43.3) 0.50
Calcium channel blockers (%) 83 (31.5) 93 (13.2) \0.001 42 (28) 36 (24) 0.50
Corticosteroids (%) 38 (14.2) 114 (16.2) 0.47 27 (18) 29 (19.3) 0.87
Diuretics (%) 90 (33.7) 160 (22.7) 0.001 47 (31.3) 48 (32) 1
Insulin (%) 57 (21.3) 62 (8.8) \0.001 29 (19.3) 29 (19.3) 1
NSAIDs and COX II inhibitors (%) 23 (8.6) 89 (12.6) 0.10 13 (8.7) 11 (7.3) 0.84
Oral antidiabetic drugs (%) 62 (23.2) 66 (9.4) \0.001 26 (17.3) 30 (20) 0.66
Other antiarrhythmic drugs (%) 13 (4.9) 37 (5.2) 0.87 6 (4) 8 (5.3) 0.79
Statins (%) 182 (68.2) 129 (18.3) \0.001 84 (56) 86 (57.3) 0.87
Antiplatelet therapy
Acetylsalicylic acid (%) 256 (95.9) 141 (94)
Clopidogrel (%) 43 (16.1) 20 (13.3)
Dipyridamole (%) 33 (12.4) 19 (12.7)
Prasugrel (%) 2 (0.7) 1 (0.7)
Severity of disease in first 24 h
APACHE IV score, median [IQR] 83 [67–107] 80 [63–102] 0.06 83 [66–105] 83 [64–104] 0.96
APACHE IV APS, median [IQR] 67 [52–90] 68 [51–86] 0.57 66 [51–88] 68 [49–87] 0.85
SOFA score, median [IQR]b 7 [5–9] 7 [5–9] 0.31 7 [5–10] 8 [5–9] 0.55
Organ failure (%) 228 (85.4) 595 (84.4) 0.50 130 (86.7) 125 (83.3) 0.79
Shock (%) 86 (32.2) 239 (33.9) 0.67 47 (31.3) 52 (34.7) 0.60
Treatment during first 24 h
Mechanical ventilation (%) 209 (78.3) 545 (77.3) 0.80 117 (78) 113 (75.3) 0.70
Renal replacement therapy (%) 34 (12.7) 68 (9.6) 0.19 16 (10.7) 19 (12.7) 0.72
ACE angiotensin-converting enzyme, APACHE acute physiology
and chronic health evaluation, APS acute physiology score, ARBs
angiotensin receptor blockers, BMI body mass index, COPD
chronic obstructive pulmonary disease, IQR interquartile range,
NSAIDs non-steroidal anti-inflammatory drugs, SD standard devi-
ation, SOFA sequential organ failure assessment
a Age not included in score
b Central nervous system not included in score
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definition, we found that antiplatelet therapy was not
associated with a different outcome (Supplemental
Tables 6 and 7).
Host response biomarkers
To obtain insight into the association between chronic
antiplatelet therapy and hallmark host responses, we
measured 19 biomarkers providing insight into activation
of coagulation (platelet counts, D-dimer, protein C,
antithrombin), endothelial cell activation (sE-selectin,
sICAM-1, angiopoietin-1, angiopoietin-2), renal injury
(creatinine, NGAL, and cystatin C), release of proin-
flammatory (TNF-a, IL-1b, IL-6, IL-8) and anti-
inflammatory cytokines (IL-10, IL-13), and release of
metalloproteinases (MMP-8 and TIMP-1) in blood
obtained within 24 h after admission (day 0) and days 2
and 4. Table 4 shows biomarker values in the propensity-
matched cohort; biomarkers measured in the unmatched
cohort are provided in Supplemental Table 8. As expec-
ted [22], biomarkers measured in sepsis patients differed
significantly from those measured in controls (Supple-
mental Table 9). In the unmatched cohort platelet counts
overall were higher in patients using antiplatelet therapy
versus patients not on antiplatelet therapy (p = 0.002), in
particular on days 0 and 2 of ICU admission, but this
difference was not present anymore in the propensity-
matched cohort. In addition, plasma creatinine was ele-
vated in antiplatelet users at all timepoints in the
Table 2 Outcomes of unmatched and propensity-matched patients














Length of stay ICU, median, days [IQR] 4 [2–9] 5 [2–10] 0.23 4 [2–9] 4 [1–10] 0.69
Organ failure during admission (%) 228 (85.4) 595 (84.4) 0.50 137 (91.3) 132 (88) 0.34
Shock during admission (%) 86 (32.2) 239 (33.9) 0.67 59 (39.3) 65 (43.3) 0.54
Mortality
ICU mortality (%) 52 (19.5) 150 (21.3) 0.60 31 (20.7) 29 (19.3) 0.88
30-day mortality (%) 82 (30.7) 196 (27.8) 0.44 47 (31.3) 41 (27.3) 0.63
60-day mortality (%) 94 (35.2) 237 (33.6) 0.71 52 (34.7) 50 (33.3) 1
90-day mortality (%) 98 (36.7) 263 (37.3) 0.83 55 (36.7) 61 (40.7) 0.54
ICU intensive care unit, IQR interquartile range
Table 3 Association of antiplatelet therapy with 30-day mortality using Cox proportional hazards regression in unmatched and
propensity-matched cohort
Unmatched cohort Propensity-matched cohort Unmatched cohort adjusted for propensity
HR 95 % CI p HR 95 % CI p HR 95 % CI p
Antiplatelet therapy 1.05 0.81–1.36 0.69 1.21 0.79–1.84 0.38 1.22 0.88–1.70 0.23
APS 1.02 1.02–1.03 \0.0001 1.02 1.01–1.02 \0.0001 1.02 1.02–1.03 \0.0001
APS acute physiology score, HR hazard ratio, CI confidence interval
Fig. 1 Impact of antiplatelet
therapy on survival. Kaplan–
Meier plots of survival time up
to 90 days after intensive care
unit admission for the




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































unmatched but not in the matched cohort. IL-10 levels
were slightly decreased in antiplatelet drug users com-
pared to non-users, most notably on days 2 and 4;
however, no significance remained in the propensity-
matched cohort. Antiplatelet therapy did not alter the
plasma levels of any of the other biomarkers in either the
unmatched or the propensity-matched cohort.
Discussion
Platelet activation has been implicated as an important
component of the deregulated host response in sepsis, and
accordingly, antiplatelet therapy exerted protective effects
in preclinical sepsis models [4, 8]. We here analyzed a
prospectively enrolled cohort of 972 well-defined patients
with sepsis and did not find an association between chronic
antiplatelet therapy and severity of illness upon ICU
admission, mortality, or biomarkers indicative of key host
responses to severe infection. These data strongly argue
against a beneficial effect of pre-existing antiplatelet therapy
on sepsis severity or outcome in critically ill patients.
Four earlier retrospective studies investigated the effect
of chronic antiplatelet therapy on mortality of patients with
sepsis, severe sepsis, and septic shock, reporting variable
results [9, 23–25]. One study entailed patients admitted to a
medical ICUwith severe sepsis or septic shock, and it found
no impact of chronic antiplatelet therapy after adjusting for
the propensity to receive antiplatelet therapy and severity of
illness as calculated by APACHE III score [23]. The other
investigation encompassed patients admitted to the ICU
with a systemic inflammatory response syndrome (SIRS),
of which a subgroup was classified as sepsis; propensity
analysis showed a reduction in mortality in acetylsalicylic
acid users in both the overall SIRS population and the sepsis
subgroup [25]. While both studies adjusted for concurrent
statin use in their propensity analyses, other chronic med-
ication use was not taken into account [23, 25]. The third
study performed regression analysis to establish the effect
of chronic antiplatelet medication on sepsis outcome and
reported an association between low-dose acetylsalicylic
acid therapy with decreased ICU or hospital mortality [24].
Another report investigated the continuous use of acetyl-
salicylic acid during ICUstay and reported results similar to
the previously mentioned study [26]. A very recent inves-
tigation used a medical claims database to report an
association between chronic antiplatelet treatment and a
reduced sepsis mortality [9]. Our study is different from
these previous reports in several aspects. Most importantly,
we prospectively enrolled patients and classified patients as
having sepsis on the basis of strict diagnostic criteria. In
addition,weperformedpropensitymatchingwhich enabled
us to create comparable cohorts with respect to many
important patient characteristics.
While platelets have been implicated in multiple
inflammatory and procoagulant reactions, and thereby in
the development of sepsis complications such as
microvascular dysfunction, disseminated intravascular
coagulation, and multiple organ failure [2, 4–6], knowl-
edge of the effect of antiplatelet therapy on the host
response to sepsis in patients is highly limited. Critically
ill patients on acetylsalicylic acid had higher plasma fib-
rinogen levels in one study [24], which is difficult to
interpret since fibrinogen is essential for fibrin formation
and thus coagulation, but is also an acute phase protein.
We measured 19 biomarkers indicative of important host
response to sepsis on admission to the ICU, and at days 2
and 4. In the unmatched cohort we found some evidence
of reduced platelet activation in patients on antiplatelet
drugs, as reflected by higher platelet counts. However, the
difference between users and non-users was not present
anymore in the propensity-matched cohort. Besides their
role in primary hemostasis, platelets facilitate activation
of the coagulation system by assembling coagulation
factor complexes on their surface and catalyzing the
generation of thrombin [27]. In addition, platelets can
enhance endothelial cell activation during sepsis via
CD40 ligand on their cell membrane and platelet-secreted
microparticles [4]. Nonetheless, we did not find any evi-
dence for an effect of antiplatelet therapy on coagulation
or endothelial cell activation in our study. Platelets can
release several cytokines from their a-granules [6], and
platelets can form complexes with leukocytes, thereby
influencing leukocyte effector functions and cytokine
secretion [28–30]. In accordance, long-term clopidogrel
treatment was associated with reduced TNF-a and IL-13
levels in patients with cardiac disease undergoing non-
emergent stenting [31] and several antiplatelet agents
were shown to inhibit intracellular leukocyte TNF-a and
IL-8 responses upon acute stroke [32]. However, in the
current investigation antiplatelet therapy was not associ-
ated with statistically significant differences in the plasma
levels of pro-inflammatory cytokines in patients with
sepsis. Moreover, antiplatelet therapy was not associated
with alterations in MMP-8 or TIMP-1 levels, which were
previously described to be elevated in patients with sepsis
[33] and have been suggested to contribute to many
inflammatory reactions during severe infection [34]. The
similarity of biomarkers in antiplatelet users and non-
users does not corroborate with the results from many
preclinical studies showing benefit from antiplatelet
therapy during infection or inflammation [4, 8]. Even in
our well-defined cohort, sepsis patients are heterogeneous
in terms of site and microbiology of the infection, disease
severity, genetic background, age, and comorbidity, and
plasma biomarker concentrations demonstrated a large
inter-individual variability, which may explain the lack of
effect by antiplatelet therapy. In addition, the dose at
which antiplatelet therapy is administered to patients may
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be insufficient to alter the strong inflammatory and pro-
coagulant responses induced by severe sepsis.
A strength of our study is the prospectively enrolled
cohort in which patients were meticulously classified and
followed daily. We performed propensity matching,
which enabled us to specifically evaluate the effect of
antiplatelet therapy, by catering for differences in baseline
characteristics between users and non-users. Nonetheless,
it remains possible that a bias remained as a result of
unmeasured confounders, an important limitation of
propensity score analyses. Considering that after
propensity matching 150 patients per group remained to
evaluate differences between those who did and those
who did not use chronic antiplatelet therapy, the possi-
bility of false negative results exists. However, the
number of patients needed in the propensity-matched
analysis to detect a statistically significant difference
between groups with a power of 80 % would be more
than 2000 per group for mortality and from more than 330
to more than 150,000 per group for individual biomark-
ers. While these numbers are difficult to achieve, they
also raise doubt about the clinical and biological rele-
vance of potential differences not revealed in our
analyses. Additional limitations are the lack of informa-
tion about the indication for, dosing of, and adherence to
antiplatelet therapy; the lack of information about bleed-
ing complications; and the fact that this study was
performed in two centers in the Netherlands and may not
reflect general ICU practice. Also, we were not able to
investigate whether chronic antiplatelet therapy influences
sepsis progression before ICU admission; with the current
study we cannot rule out that antiplatelet therapy has
beneficial effects in early stages of sepsis.
Conclusion
In this prospectively assembled cohort of 972 well-de-
fined patients with sepsis we did not find an association
between chronic antiplatelet therapy and severity of ill-
ness or outcome. Additionally, no differences in
biomarkers indicative of key host responses to sepsis were
found between patients who did and who did not receive
chronic antiplatelet therapy. Our data strongly argue
against a beneficial effect of pre-existing antiplatelet
therapy on sepsis severity or outcome.
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